A new mathematical model suggests that the development of a vaccine against HIV, even if it is only partially effective, could be hugely important for the elimination of HIV worldwide.
Browsing: Clinical > Vaccines
A Phase I clinical trial has demonstrated two investigational Ebola vaccines generate a durable immune response 1 year after vaccination.
Despite an urgent need for a universal flu vaccine there is no such vaccine in the market and no regulatory guideline for its approval. This special report from Future Virology proposes a stepwise process for regulatory and marketing approval for such a vaccine and discusses the epitope-based vaccine candidate Multimeric-001 (M-001).
The first study to investigate attitudes to the child flu vaccine in the UK has reported that concerns around the vaccines safety, efficiency and side effects may be reducing uptake.
We at Infectious Diseases Hub recently spoke to Peter Openshaw, Professor of Experimental Medicine at Imperial College London (UK), about his research into respiratory viruses and the challenges currently facing science policy and funding.
The National Institutes of Health (MD, USA) have begun a Phase I clinical trial examining a vaccine intended to provide broad protection against a range of mosquito-borne diseases by targeting the insect’s saliva.
Researchers have demonstrated that a new whole-parasite vaccine could provide up to 100% protection in clinical trials carried out at the University of Tübingen (Germany).
Researchers have created a model to assess the benefits of vaccination on the burden of non-typhoidal salmonella in Mali; the research could inform policy in many countries where there is high risk of these infections.
Researchers have pioneered an mRNA-based vaccine against Zika that has demonstrated promising results in pre-clinical trials on mice and monkeys.